Internal Medicine, Endocrinology, Diabetes, & Metabolism · Carson City, NV
NPI
1811339013
Since 2013
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2874 N Carson St Ste 120
Carson City, NV, 89706
Phone (775) 888-6513
Groups this clinician bills Medicare through
Medicare paid, 2024
$129K
2,350 services
Medicare patients, 2024
531
Average age 74
Drug cost, 2024
$2.8M
3,844 prescriptions
Company payments, 2025
$2,410
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Eng Keong Tan was code 99214 (office e&m - established), 1,116 times for 499 patients. In total Eng Keong Tan billed 2,350 services in 12 codes, and Medicare paid $129K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-09-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,116 | 499 | $89.92 | $100K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 709 | 382 | $12.00 | $8,509 |
| 95251 Test - Miscellaneous | Office | 409 | 166 | $25.29 | $10K |
| 99204 Office E&M - New | Office | 52 | 52 | $117.36 | $6,103 |
| 99213 Office E&M - Established | Office | 39 | 34 | $61.67 | $2,405 |
By year: 2022 $144K for 2,068 services; 2023 $113K for 2,055 services; 2024 $129K for 2,350 services.
Medicare prescription drug claims, 2024
In 2024, the drug Eng Keong Tan prescribed most often to Medicare patients was Levothyroxine Sodium, with 600 prescriptions and refills. In total Eng Keong Tan wrote 3,844 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 600 | 1,759 | 212 | $7,465 |
| Alendronate Sodium Generic | 225 | 592 | 80 | $2,427 |
| Ozempic Semaglutide | 223 | 417 | 79 | $382K |
| Metformin Hcl Generic | 213 | 629 | 105 | $2,516 |
| Synthroid Levothyroxine Sodium | 171 | 490 | 65 | $18K |
| Jardiance Empagliflozin | 144 | 381 | 59 | $219K |
| Liothyronine Sodium Generic | 138 | 402 | 53 | $6,157 |
| Trulicity Dulaglutide | 121 | 239 | 45 | $231K |
| Glipizide Generic | 119 | 317 | 54 | $657 |
| Mounjaro Tirzepatide | 118 | 195 | 32 | $196K |
| Methimazole Generic | 117 | 338 | 52 | $1,481 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 84 | 221 | 43 | $12K |
| Novolog Flexpen Insulin Aspart | 72 | 207 | 41 | $28K |
| Hydrocortisone Generic | 69 | 184 | 30 | $6,409 |
| Tresiba Flextouch U-100 Insulin Degludec | 63 | 176 | 37 | $56K |
Brand drugs: 1,843 claims; generic drugs: 1,804 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Eng Keong Tan $2,410 ($2,410 in general payments such as food, travel and fees) from 23 companies. The largest payer was Insulet Corporation with $361.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 14 | $361 |
| Amgen Inc. AMGN | 4 | $251 |
| Ascendis Pharma Endocrinology Inc ASND | 4 | $195 |
| Medtronic, Inc. MDT | 11 | $188 |
| Mannkind Corporation MNKD | 4 | $169 |
| Lilly USA, LLC LLY | 3 | $147 |
| Recordati_rare_diseases_inc. | 2 | $132 |
| Soleno Therapeutics, Inc. SLNO | 1 | $119 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $118 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $116 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.